Clinical Trial Detail

NCT ID NCT03041701
Title Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

alveolar rhabdomyosarcoma

embryonal rhabdomyosarcoma

Therapies

Dasatinib + Ganitumab

Age Groups: adult senior child

No variant requirements are available.